Pacer Advisors Inc. Has $4.26 Million Position in Xilinx, Inc. (NASDAQ:XLNX)

Share on StockTwits

Pacer Advisors Inc. grew its holdings in Xilinx, Inc. (NASDAQ:XLNX) by 8.8% during the 3rd quarter, HoldingsChannel reports. The firm owned 44,391 shares of the programmable devices maker’s stock after acquiring an additional 3,594 shares during the quarter. Pacer Advisors Inc.’s holdings in Xilinx were worth $4,257,000 as of its most recent filing with the SEC.

Several other large investors have also modified their holdings of XLNX. Krane Funds Advisors LLC acquired a new stake in shares of Xilinx in the second quarter valued at about $29,000. Citizens Financial Group Inc RI grew its position in shares of Xilinx by 114.2% in the second quarter. Citizens Financial Group Inc RI now owns 257 shares of the programmable devices maker’s stock valued at $30,000 after purchasing an additional 137 shares during the last quarter. Lenox Wealth Advisors LLC acquired a new stake in shares of Xilinx in the second quarter valued at about $33,000. FinTrust Capital Advisors LLC grew its position in shares of Xilinx by 168.0% in the second quarter. FinTrust Capital Advisors LLC now owns 276 shares of the programmable devices maker’s stock valued at $33,000 after purchasing an additional 173 shares during the last quarter. Finally, Cribstone Capital Management LLC grew its position in shares of Xilinx by 181.3% in the second quarter. Cribstone Capital Management LLC now owns 450 shares of the programmable devices maker’s stock valued at $53,000 after purchasing an additional 290 shares during the last quarter. 84.77% of the stock is currently owned by institutional investors.

In other news, SVP Emre Onder sold 2,222 shares of Xilinx stock in a transaction that occurred on Monday, July 29th. The shares were sold at an average price of $120.78, for a total value of $268,373.16. Following the completion of the transaction, the senior vice president now owns 3,239 shares in the company, valued at $391,206.42. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Salil Raje sold 5,000 shares of Xilinx stock in a transaction that occurred on Monday, July 29th. The shares were sold at an average price of $120.78, for a total transaction of $603,900.00. Following the completion of the transaction, the executive vice president now owns 24,455 shares of the company’s stock, valued at approximately $2,953,674.90. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 25,711 shares of company stock valued at $2,804,633. Corporate insiders own 0.19% of the company’s stock.

Shares of XLNX opened at $96.22 on Friday. The stock has a market cap of $22.86 billion, a price-to-earnings ratio of 27.65, a P/E/G ratio of 2.02 and a beta of 1.25. The company has a quick ratio of 6.54, a current ratio of 7.22 and a debt-to-equity ratio of 0.48. Xilinx, Inc. has a 12 month low of $68.76 and a 12 month high of $141.60. The company has a 50-day moving average price of $99.84 and a two-hundred day moving average price of $112.24.

Xilinx (NASDAQ:XLNX) last announced its quarterly earnings results on Wednesday, July 24th. The programmable devices maker reported $0.97 EPS for the quarter, topping analysts’ consensus estimates of $0.94 by $0.03. The firm had revenue of $849.60 million during the quarter, compared to analysts’ expectations of $849.76 million. Xilinx had a net margin of 29.19% and a return on equity of 35.99%. The company’s revenue for the quarter was up 24.1% compared to the same quarter last year. During the same quarter last year, the company earned $0.74 earnings per share. Equities research analysts expect that Xilinx, Inc. will post 3.74 EPS for the current fiscal year.

Several equities research analysts recently weighed in on XLNX shares. SunTrust Banks reduced their target price on shares of Xilinx from $127.00 to $105.00 and set a “hold” rating for the company in a research note on Wednesday, October 2nd. Benchmark started coverage on shares of Xilinx in a research note on Tuesday, July 23rd. They issued a “hold” rating for the company. Morgan Stanley increased their target price on shares of Xilinx from $126.00 to $134.00 and gave the company an “overweight” rating in a research note on Thursday, July 25th. ValuEngine cut shares of Xilinx from a “hold” rating to a “sell” rating in a research note on Wednesday, October 2nd. Finally, Rosenblatt Securities reiterated a “buy” rating and issued a $165.00 target price on shares of Xilinx in a research note on Tuesday, October 1st. Two investment analysts have rated the stock with a sell rating, fourteen have given a hold rating and eleven have issued a buy rating to the stock. The company currently has an average rating of “Hold” and a consensus target price of $119.14.

About Xilinx

Xilinx, Inc designs and develops programmable devices and associated technologies worldwide. Its programmable devices comprise integrated circuits (ICs) in the form of programmable logic devices (PLDs), such as programmable system on chips, and three dimensional ICs; adaptive compute acceleration platform; software design tools to program the PLDs; software development environments and embedded platforms; targeted reference designs; printed circuit boards; and intellectual property (IP) core licenses covering Ethernet, memory controllers, Interlaken, and peripheral component interconnect express interfaces, as well as domain-specific IP in the areas of embedded, digital signal processing and connectivity, and market-specific IP cores.

Further Reading: Technical Analysis

Want to see what other hedge funds are holding XLNX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Xilinx, Inc. (NASDAQ:XLNX).

Institutional Ownership by Quarter for Xilinx (NASDAQ:XLNX)

Receive News & Ratings for Xilinx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xilinx and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


 
© 2006-2019 BBNS.